CEL-SCI Corporation (NYSEMKT:CVM) is having an overwhelmingly strong day in the market today and for good reason. It looks like the company is going to get its hands on a patent it was after. As a result, investor excitement ensued, leading to gains in the stock and prompting our partners at Trade Ideas to send the alert. At the moment (11:17), CVM is trading at $0.14 per share after a gain of $0.04 per share or 36.36% thus far today.
CVM Will Be Getting A New Patent
As mentioned above, CEL-SCI is having a strong day in the market today after announcing that it will be receiving a new European patent on Multikine* (injections of Leukocyte Interleukin). Multikine* is an investigational cancer immunotherapy. The patent that the company will soon receive is titled A METHOD FOR MODULATING HLA CLASS II TUMOR CELL SURFACE EXPRESSION WITH CYTOKINE MIXTURE. In a statement, Geert Kersten, CEO at CVM had the following to offer…
“Our patent portfolio for Multikine consists of multiple patents issued in the United States, Europe, China and Japan. In addition to these patents that offer certain protections for Multikine, the method of manufacture for Multikine held by CEL-SCI as trade secret offers additional protections.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on CVM. In particular, we’re interested in following the company through the ongoing development of Multikine*, as the treatment seems to be promising in early stages. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!